Determinants of metastatic competency in colorectal cancer

Molecular Oncology

Volumn 11, Issue 1, 2017, Pages 97-119

  Tauriello, Daniele V F ^a   Calon, Alexandre ^b   Lonardo, Enza ^a   Batlle, Eduard ^a,c  

^a INSTITUTE FOR RESEARCH IN BIOMEDICINE   (Spain)

^b HOSPITAL DEL MAR   (Spain)

^c INSTITUCIÓ CATALANA DE RECERCA I ESTUDIS AVANÇATS ICREA   (Spain)

Author keywords

Cancer immunology; Cancer stem cells; Clonal diversity; Combination therapy; Dormancy; Heterogeneity; Immunotherapy; Stroma; TGF beta; Tumour microenvironment Correspondence

Indexed keywords

ADAPTIVE IMMUNITY; CANCER ASSOCIATED FIBROBLAST; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER STEM CELL; CELL INVASION; COLON CARCINOGENESIS; ENDOTHELIUM CELL; HUMAN; IMMUNOCOMPETENT CELL; INNATE IMMUNITY; INTESTINE MUCOSA; METASTATIC COLORECTAL CANCER; NONHUMAN; PRIORITY JOURNAL; REVIEW; TUMOR MICROENVIRONMENT; ANIMAL; CARCINOGENESIS; COLON; COLORECTAL TUMOR; IMMUNOLOGY; IMMUNOTHERAPY; METASTASIS; MOLECULARLY TARGETED THERAPY; PATHOLOGY; PROCEDURES; PROGNOSIS; RECTUM;

ANIMALS; CARCINOGENESIS; COLON; COLORECTAL NEOPLASMS; HUMANS; IMMUNOTHERAPY; MOLECULAR TARGETED THERAPY; NEOPLASM METASTASIS; NEOPLASTIC STEM CELLS; PROGNOSIS; RECTUM; TUMOR MICROENVIRONMENT;

EID: 85021111135     PISSN: 15747891     EISSN: 18780261     Source Type: Journal    
DOI: 10.1002/1878-0261.12018     Document Type: Review

References (194)

1. Akhurst RJ and Hata A (2012) Targeting the TGFbeta signalling pathway in disease. Nat Rev Drug Discov 11, 790-811.
2. Anastas JN and Moon RT (2012) WNT signalling pathways as therapeutic targets in cancer. Nat Rev Cancer 13, 11-26.
3. Andrè T, Boni C, Navarro M, Tabernero J, Hickish T, Topham C, Bonetti A, Clingan P, Bridgewater J, Rivera F et al. (2009) Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol 27, 3109-3116.
4. Bao S, Ouyang G, Bai X, Huang Z, Ma C, Liu M, Shao R, Anderson RM, Rich JN and Wang XF (2004) Periostin potently promotes metastatic growth of colon cancer by augmenting cell survival via the Akt/PKB pathway. Cancer Cell 5, 329-339.
5. Barker N, Ridgway RA, van Es JH, van de Wetering M, Begthel H, van den Born M, Danenberg E, Clarke AR, Sansom OJ and Clevers H (2008) Crypt stem cells as the cells-of-origin of intestinal cancer. Nature 457, 608-611.
6. Becht E, de Reyniès A, Giraldo NA, Pilati C, Buttard B, Lacroix L, Sèlves J, Sautes-Fridman C, Laurent-Puig P and Fridman W-H (2016) Immune and stromal classification of colorectal cancer is associated with molecular subtypes and relevant for precision immunotherapy. Clin Cancer Res 22, 4057-4066.
7. Berdiel-Acer M, Sanz-Pamplona R, Calon A, Cuadras D, Berenguer A, Sanjuan X, Paules MJ, Salazar R, Moreno V, Batlle E et al. (2014) Differences between CAFs and their paired NCF from adjacent colonic mucosa reveal functional heterogeneity of CAFs, providing prognostic information. Mol Oncol 8, 1290-1305.
8. Bertotti A, Papp E, Jones S, Adleff V, Anagnostou V, Lupo B, Sausen M, Phallen J, Hruban CA, Tokheim C et al. (2015) The genomic landscape of response to EGFR blockade in colorectal cancer. Nature 526, 263-267.
9. Bishehsari F, Mahdavinia M, Vacca M, Malekzadeh R and Mariani-Costantini R (2014) Epidemiological transition of colorectal cancer in developing countries: environmental factors, molecular pathways, and opportunities for prevention. World J Gastroenterol 20, 6055-6072.
10. Blanco-Calvo M, Concha À, Figueroa A, Garrido F and Valladares-Ayerbes M (2015) Colorectal cancer classification and cell heterogeneity: a systems oncology approach. Int J Mol Sci 16, 13610-13632.
11. Boland CR and Goel A (2005) Somatic evolution of cancer cells. Semin Cancer Biol 15, 436-450.
12. Brabletz T, Jung A, Hermann K, Gunther K, Hohenberger W and Kirchner T (1998) Nuclear overexpression of the oncoprotein beta-catenin in colorectal cancer is localized predominantly at the invasion front. Pathol Res Pract 194, 701-704.
13. Braster R, Bogels M, Beelen RHJ and van Egmond M (2015) The delicate balance of macrophages in colorectal cancer; their role in tumour development and therapeutic potential. Immunobiology 222, 21-30.
14. Buczacki SJA, Zecchini HI, Nicholson AM, Russell R, Vermeulen L, Kemp R and Winton DJ (2013) Intestinal label-retaining cells are secretory precursors expressing Lgr5. Nature 495, 65-69.
15. Budinska E, Popovici V, Tejpar S, D’Ario G, Lapique N, Sikora KO, Di Narzo AF, Yan P, Graeme Hodgson J, Weinrich S et al. (2013) Gene expression patterns unveil a new level of molecular heterogeneity in colorectal cancer. J Pathol 231, 63-76.
16. Butler JM, Kobayashi H and Rafii S (2010) Instructive role of the vascular niche in promoting tumour growth and tissue repair by angiocrine factors. Nat Rev Cancer 10, 138-146.
17. Butterfield LH (2015) Cancer vaccines. BMJ 350, h988.
18. Calon A, Espinet E, Palomo-Ponce S, Tauriello DVF, Iglesias M, Cespedes MV, Sevillano M, Nadal C, Jung P, Zhang XH-FF et al. (2012) Dependency of colorectal cancer on a TGF-b-driven program in stromal cells for metastasis initiation. Cancer Cell 22, 571-584.
19. Calon A, Lonardo E, Berenguer-llergo A, Espinet E, Hernando-momblona X, Iglesias M, Sevillano M, Palomo-ponce S, Tauriello DVF, Byrom D et al. (2015) Stromal gene expression defines poor-prognosis subtypes in colorectal cancer. Nat Genet 47, 320-329.
20. Calon A, Tauriello DVF and Batlle E (2014) TGF-beta in CAF-mediated tumor growth and metastasis. Semin Cancer Biol 25, 15-22.
21. Cancer Genome Atlas Network (2012) Comprehensive molecular characterization of human colon and rectal cancer. Nature 487, 330-337.
22. Catarinella M, Monestiroli A, Escobar G, Fiocchi A, Tran NL, Aiolfi R, Marra P, Esposito A, Cipriani F, Aldrighetti L et al. (2016) IFNa gene/cell therapy curbs colorectal cancer colonization of the liver by acting on the hepatic microenvironment. EMBO Mol Med 8, 155-170.
23. Chen ML, Pittet MJ, Gorelik L, Flavell RA, Weissleder R, von Boehmer H and Khazaie K (2005) Regulatory T cells suppress tumor-specific CD8 T cell cytotoxicity through TGF-beta signals in vivo. Proc Natl Acad Sci USA 102, 419-424.
24. Chun E, Lavoie S, Michaud M, Gallini CA, Kim J, Soucy G, Odze R, Glickman JN and Garrett WS (2015) CCL2 promotes colorectal carcinogenesis by enhancing polymorphonuclear myeloid-derived suppressor cell population and function. Cell Rep 12, 244-257.
25. Clevers H (2013) The intestinal crypt, a prototype stem cell compartment. Cell 154, 274-284.
26. Collignon FP, Holland EC and Feng S (2004) Organ donors with malignant gliomas: an update. Am J Transplant 4, 15-21.
27. Dalerba P, Dylla SJ, Park I-K, Liu R, Wang X, Cho RW, Hoey T, Gurney A, Huang EH, Simeone DM et al. (2007) Phenotypic characterization of human colorectal cancer stem cells. Proc Natl Acad Sci USA 104, 10158-10163.
28. Dalerba P, Kalisky T, Sahoo D, Rajendran PS, Rothenberg ME, Leyrat AA, Sim S, Okamoto J, Johnston DM, Qian D et al. (2011) Single-cell dissection of transcriptional heterogeneity in human colon tumors. Nat Biotechnol 29, 1120-1127.
29. Davis H, Irshad S, Bansal M, Rafferty H, Boitsova T, Bardella C, Jaeger E, Lewis A, Freeman-Mills L, Giner FC et al. (2014) Aberrant epithelial GREM1 expression initiates colonic tumorigenesis from cells outside the stem cell niche. Nat Med 21, 62-70.
30. Dawson H and Lugli A (2015) Molecular and pathogenetic aspects of tumor budding in colorectal cancer. Front Med (Lausanne) 2, 11.
31. de Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, Boni C, Cortes-Funes H, Cervantes A, Freyer G et al. (2000) Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 18, 2938-2947.
32. De Sousa E, Melo F, Wang X, Jansen M, Fessler E, Trinh A, de Rooij LPMH, de Jong JH, de Boer OJ, van Leersum R, Bijlsma MF et al. (2013) Poor-prognosis colon cancer is defined by a molecularly distinct subtype and develops from serrated precursor lesions. Nat Med 19, 614-618.
33. Diaz LA Jr and Le DT (2015) PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med 373, 1979.
34. Diaz LA Jr, Williams RT, Wu J, Kinde I, Hecht JR, Berlin J, Allen B, Bozic I, Reiter JG, Nowak MA et al. (2012) The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature 486, 537.
35. Dieter SM, Ball CR, Hoffmann CM, Nowrouzi A, Herbst F, Zavidij O, Abel U, Arens A, Weichert W, Brand K et al. (2011) Distinct types of tumor-initiating cells form human colon cancer tumors and metastases. Cell Stem Cell 9, 357-365.
36. Douillard J, Cunningham D, Roth A, Navarro M, James R, Karasek P, Jandik P, Iveson T, Carmichael J, Alakl M et al. (2000) Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 355, 1041-1047.
37. Drost J, van Jaarsveld RH, Ponsioen B, Zimberlin C, van Boxtel R, Buijs A, Sachs N, Overmeer RM, Offerhaus GJ, Begthel H et al. (2015) Sequential cancer mutations in cultured human intestinal stem cells. Nature 521, 43-47.
38. Dudley AC (2012) Tumor endothelial cells. Cold Spring Harb Perspect Med 2, a006536.
39. DuPage M, Mazumdar C, Schmidt LM, Cheung AF and Jacks T (2012) Expression of tumour-specific antigens underlies cancer immunoediting. Nature 482, 405-409.
40. Eyles J, Puaux AL, Wang X, Toh B, Prakash C, Hong M, Tan TG, Zheng L, Ong LC, Jin Y et al. (2010) Tumor cells disseminate early, but immunosurveillance limits metastatic outgrowth, in a mouse model of melanoma. J Clin Invest 120, 2030-2039.
41. Fang H and Declerck YA (2013) Targeting the tumor microenvironment: from understanding pathways to effective clinical trials. Cancer Res 73, 4965-4977.
42. Fearon ER (2011) Molecular genetics of colorectal cancer. Annu Rev Pathol 6, 479-507.
43. Fearon ER and Vogelstein B (1990) A genetic model for colorectal tumorigenesis. Cell 61, 759-767.
44. Feig C, Jones JO, Kraman M, Wells RJB, Deonarine A, Chan DS, Connell CM, Roberts EW, Zhao Q, Caballero OL et al. (2013) Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer. Proc Natl Acad Sci USA 110, 20212-20217.
45. Ferrara N and Adamis AP (2016) Ten years of anti-vascular endothelial growth factor therapy. Nat Rev Drug Discov 15, 385-403.
46. Flavell RA, Sanjabi S, Wrzesinski SH and Licona-Limon P (2010) The polarization of immune cells in the tumour environment by TGFbeta. Nat Rev Immunol 10, 554-567.
47. Fridlender ZG, Sun J, Kim S, Kapoor V, Cheng G, Ling L, Worthen GS and Albelda SM (2009) Polarization of tumor-associated neutrophil phenotype by TGF-beta: “N1” versus “N2” TAN. Cancer Cell 16, 183-194.
48. Fujii M, Shimokawa M, Date S, Takano A, Matano M, Nanki K, Ohta Y, Toshimitsu K, Nakazato Y, Kawasaki K et al. (2016) A colorectal tumor organoid library demonstrates progressive loss of niche factor requirements during tumorigenesis. Cell Stem Cell 18, 827-838.
49. Gabrilovich DI and Nagaraj S (2009) Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 9, 162-174.
50. Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pages C, Tosolini M, Camus M, Berger A, Wind P et al. (2006) Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313, 1960-1964.
51. Galon J, Mlecnik B, Bindea G, Angell HK, Berger A, Lagorce C, Lugli A, Zlobec I, Hartmann A, Bifulco C et al. (2014) Towards the introduction of the “Immunoscore” in the classification of malignant tumours. J Pathol 232, 199-209.
52. Ghajar CM (2015) Metastasis prevention by targeting the dormant niche. Nat Rev Cancer 15, 238-247.
53. Giancotti FG (2013) Mechanisms governing metastatic dormancy and reactivation. Cell 155, 750-764.
54. Giannakis M, Mu XJ, Shukla SA, Qian ZR, Cohen O, Nishihara R, Bahl S, Cao Y, Amin-Mansour A, Yamauchi M et al. (2016) Genomic correlates of immune-cell infiltrates in colorectal carcinoma. Cell Rep 15, 857-865.
55. Golub TR, Slonim DK, Tamayo P, Huard C, Gaasenbeek M, Mesirov JP, Coller H, Loh ML, Downing JR, Caligiuri MA et al. (1999) Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science 286, 531-537.
56. Gonzalez-Zubeldia I, Dotor J, Redrado M, Bleau A-M, Manrique I, de Aberasturi AL, Villalba M and Calvo A (2015) Co-migration of colon cancer cells and CAFs induced by TGFb1 enhances liver metastasis. Cell Tissue Res 359, 829-839.
57. Greaves M and Maley CC (2012) Clonal evolution in cancer. Nature 481, 306-313.
58. Guinney J, Dienstmann R, Wang X, de Reynies A, Schlicker A, Soneson C, Marisa L, Roepman P, Nyamundanda G, Angelino P et al. (2015) The consensus molecular subtypes of colorectal cancer. Nat Med 21, 1350-1356.
59. Gulubova MV, Ananiev JR, Vlaykova TI, Yovchev Y, Tsoneva V and Manolova IM (2012) Role of dendritic cells in progression and clinical outcome of colon cancer. Int J Colorectal Dis 27, 159-169.
60. Halama N, Michel S, Kloor M, Zoernig I, Benner A, Spille A, Pommerencke T, Von Knebel Doeberitz M, Folprecht G, Luber B et al. (2011) Localization and density of immune cells in the invasive margin of human colorectal cancer liver metastases are prognostic for response to chemotherapy. Cancer Res 71, 5670-5677.
61. Halama N, Michel S, Kloor M, Zoernig I, Pommerencke T, Doeberitz MVK, Schirmacher P, Weitz J, Grabe N and Jager D (2009) The localization and density of immune cells in primary tumors of human metastatic colorectal cancer shows an association with response to chemotherapy. Cancer Immun 9, 1.
62. Halama N, Zoernig I, Berthel A, Kahlert C, Klupp F, Suarez-Carmona M, Suetterlin T, Brand K, Krauss J, Lasitschka F et al. (2016) Tumoral immune cell exploitation in colorectal cancer metastases can be targeted effectively by anti-CCR5 therapy in cancer patients. Cancer Cell 29, 587-601.
63. Hanahan D and Coussens LM (2012) Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer Cell 21, 309-322.
64. Hanahan D and Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144, 646-674.
65. Hardingham JE, Grover P, Winter M, Hewett PJ, Price TJ and Thierry B (2015) Detection and clinical significance of circulating tumor cells in colorectal cancer-20 years of progress. Mol Med 21(Suppl 1), S25-S31.
66. Herrera M, Herrera A, Domınguez G, Silva J, Garcıa V, Garcıa JM, Gomez I, Soldevilla B, Munoz C, Provencio M et al. (2013) Cancer-associated fibroblast and M2 macrophage markers together predict outcome in colorectal cancer patients. Cancer Sci 104, 437-444.
67. Hirai H, Fujishita T, Kurimoto K, Miyachi H, Kitano S, Inamoto S, Itatani Y, Saitou M, Maekawa T and Taketo MM (2014) CCR1-mediated accumulation of myeloid cells in the liver microenvironment promoting mouse colon cancer metastasis. Clin Exp Metastasis 31, 977-989.
68. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E et al. (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350, 2335-2342.
69. Hwang S-Y, Deng X, Byun S, Lee C, Lee S-J, Suh H, Zhang J, Kang Q, Zhang T, Westover KD et al. (2016) Direct targeting of b-catenin by a small molecule stimulates proteasomal degradation and suppresses oncogenic Wnt/b-catenin signaling. Cell Rep 16, 28-36.
70. Iinuma H, Watanabe T, Mimori K, Adachi M, Hayashi N, Tamura J, Matsuda K, Fukushima R, Okinaga K, Sasako M et al. (2011) Clinical significance of circulating tumor cells, including cancer stem-like cells, in peripheral blood for recurrence and prognosis in patients with dukes’ stage B and C colorectal cancer. J Clin Oncol 29, 1547-1555.
71. Inamoto S, Itatani Y, Yamamoto T, Minamiguchi S, Hirai H, Iwamoto M, Hasegawa S, Taketo MM, Sakai Y and Kawada K (2016) Loss of SMAD4 promotes colorectal cancer progression by accumulation of myeloid-derived suppressor cells through the CCL15-CCR1 chemokine axis. Clin Cancer Res 22, 492-501.
72. Isella C, Terrasi A, Bellomo SE, Petti C, Galatola G, Muratore A, Mellano A, Senetta R, Cassenti A, Sonetto C et al. (2015) Stromal contribution to the colorectal cancer transcriptome. Nat Genet 47, 312-319.
73. Itatani Y, Kawada K, Fujishita T, Kakizaki F, Hirai H, Matsumoto T, Iwamoto M, Inamoto S, Hatano E, Hasegawa S et al. (2013) Loss of SMAD4 from colorectal cancer cells promotes CCL15 expression to recruit CCR1+ myeloid cells and facilitate liver metastasis. Gastroenterology 145, 1064-1075.e11.
74. Itatani Y, Kawada K, Inamoto S, Yamamoto T, Ogawa R, Taketo MM and Sakai Y (2016) The role of chemokines in promoting colorectal cancer invasion/ metastasis. Int J Mol Sci 17, 643.
75. Jain RK (2005) Antiangiogenic therapy for cancer: current and emerging concepts. Oncology (Williston Park) 19, 7-16.
76. Jones S, Chen WD, Parmigiani G, Diehl F, Beerenwinkel N, Antal T, Traulsen A, Nowak MA, Siegel C, Velculescu VE et al. (2008) Comparative lesion sequencing provides insights into tumor evolution. Proc Natl Acad Sci USA 105, 4283-4288.
77. Junttila MR, Mao W, Wang X, Wang B-E, Pham T, Flygare J, Yu S-F, Yee S, Goldenberg D, Fields C et al. (2015) Targeting LGR5+ cells with an antibody-drug conjugate for the treatment of colon cancer. Sci Transl Med 7, 314ra186.
78. Kahn M (2014) Can we safely target the WNT pathway? Nat Rev Drug Discov 13, 513-532.
79. Kalluri R (2016) The biology and function of fibroblasts in cancer. Nat Rev Cancer 16, 582-598.
80. Kang Y, Siegel PM, Shu W, Drobnjak M, Kakonen SM, Cordon-Cardo C, Guise TA and Massague J (2003) A multigenic program mediating breast cancer metastasis to bone. Cancer Cell 3, 537-549.
81. Kimura T, McKolanis JR, Dzubinski LA, Islam K, Potter DM, Salazar AM, Schoen RE and Finn OJ (2013) MUC1 vaccine for individuals with advanced adenoma of the colon: a cancer immunoprevention feasibility study. Cancer Prev Res (Phila) 6, 18-26.
82. Kitamura T, Fujishita T, Loetscher P, Revesz L, Hashida H, Kizaka-Kondoh S, Aoki M and Taketo MM (2010) Inactivation of chemokine (C-C motif) receptor 1 (CCR1) suppresses colon cancer liver metastasis by blocking accumulation of immature myeloid cells in a mouse model. Proc Natl Acad Sci USA 107, 13063-13068.
83. Kitamura T, Kometani K, Hashida H, Matsunaga A, Miyoshi H, Hosogi H, Aoki M, Oshima M, Hattori M, Takabayashi A et al. (2007) SMAD4-deficient intestinal tumors recruit CCR1+ myeloid cells that promote invasion. Nat Genet 39, 467-475.
84. Kloor M, Michel S and von Knebel Doeberitz M (2010) Immune evasion of microsatellite unstable colorectal cancers. Int J Cancer 127, 1001-1010.
85. Kloor M and von Knebel Doeberitz M (2016) The immune biology of microsatellite-unstable cancer. Trends Cancer 2, 121-133.
86. Kozar S, Morrissey E, Nicholson AM, Van der Heijden M, Zecchini HI, Kemp R, Tavare S, Vermeulen L and Winton DJ (2013) Continuous clonal labeling reveals small numbers of functional stem cells in intestinal crypts and adenomas. Cell Stem Cell 13, 626-633.
87. Kraman M, Bambrough PJ, Arnold JN, Roberts EW, Magiera L, Jones JO, Gopinathan A, Tuveson DA and Fearon DT (2010) Suppression of antitumor immunity by stromal cells expressing fibroblast activation protein-alpha. Science 330, 827-830.
88. Kreso A, Brien CAO, Galen P Van, Gan O, Notta F, Brown AMK, Ng K, Ma J, Wienholds E, Dunant C et al. (2012) Variable clonal repopulation dynamics influence chemotherapy response in colorectal cancer. Science 339, 543-548.
89. Kreso A and Dick JE (2014) Evolution of the cancer stem cell model. Cell Stem Cell 14, 275-291.
90. Kreso A, van Galen P, Pedley NM, Lima-Fernandes E, Frelin C, Davis T, Cao L, Baiazitov R, Du W, Sydorenko N et al. (2014) Self-renewal as a therapeutic target in human colorectal cancer. Nat Med 20, 29-36.
91. Kryczek I, Lin Y, Nagarsheth N, Peng D, Zhao L, Zhao E, Vatan L, Szeliga W, Dou Y, Owens S et al. (2014) IL-22+ CD4+ T cells promote colorectal cancer stemness via STAT3 transcription factor activation and induction of the methyltransferase DOT1L. Immunity 40, 772-784.
92. Li M-X, Liu X-M, Zhang X-F, Zhang J-F, Wang W-L, Zhu Y, Dong J, Cheng J-W, Liu Z-W, Ma L et al. (2014) Prognostic role of neutrophil-to-lymphocyte ratio in colorectal cancer: a systematic review and meta-analysis. Int J Cancer 134, 2403-2413.
93. Li HJ, Reinhardt F, Herschman HR and Weinberg RA (2012) Cancer-stimulated mesenchymal stem cells create a carcinoma stem cell niche via prostaglandin E2 Signaling. Cancer Discov 2, 840-855.
94. Liska D, Chen CT, Bachleitner-Hofmann T, Christensen JG and Weiser MR (2011) HGF rescues colorectal cancer cells from EGFR inhibition via MET activation. Clin Cancer Res 17, 472-482.
95. Liu C, Billadeau DD, Abdelhakim H, Leof E, Kaibuchi K, Bernabeu C, Bloom GS, Yang L, Boardman L, Shah VH et al. (2013) IQGAP1 suppresses TbRII-mediated myofibroblastic activation and metastatic growth in liver. J Clin Invest 123, 1138-1156.
96. Liu C, Li J, Xiang X, Guo L, Tu K, Liu Q, Shah VH and Kang N (2014) PDGF receptor-a promotes TGF-b signaling in hepatic stellate cells via transcriptional and posttranscriptional regulation of TGF-b receptors. Am J Physiol Gastrointest Liver Physiol 307, G749-G759.
97. Llosa NJ, Cruise M, Tam A, Wicks EC, Hechenbleikner EM, Taube JM, Blosser RL, Fan H, Wang H, Luber BS et al. (2015) The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints. Cancer Discov 5, 43-51.
98. Lombardo Y, Scopelliti A, Cammareri P, Todaro M, Iovino F, Ricci-Vitiani L, Gulotta G, Dieli F, De Maria R and Stassi G (2011) Bone morphogenetic protein 4 induces differentiation of colorectal cancer stem cells and increases their response to chemotherapy in mice. Gastroenterology 140, 297-309.
99. Lotti F, Jarrar AM, Pai RK, Hitomi M, Lathia J, Mace A, Gantt GA, Sukhdeo K, DeVecchio J, Vasanji A et al. (2013) Chemotherapy activates cancer-associated fibroblasts to maintain colorectal cancer-initiating cells by IL-17A. J Exp Med 210, 2851-2872.
100. Lu J, Ye X, Fan F, Xia L, Bhattacharya R, Bellister S, Tozzi F, Sceusi E, Zhou Y, Tachibana I et al. (2013) Endothelial cells promote the colorectal cancer stem cell phenotype through a soluble form of Jagged-1. Cancer Cell 23, 171-185.
101. Mahmoudi T, Li VS, Ng SS, Taouatas N, Vries RG, Mohammed S, Heck AJ and Clevers H (2009) The kinase TNIK is an essential activator of Wnt target genes. EMBO J 28, 3329-3340.
102. Malladi S, Macalinao DG, Jin X, He L, Basnet H, Zou Y, de Stanchina E and Massague J (2016) Metastatic latency and immune evasion through autocrine inhibition of WNT. Cell 165, 45-60.
103. Mantovani A and Allavena P (2015) The interaction of anticancer therapies with tumor-associated macrophages. J Exp Med 212, 435-445.
104. Mantovani A, Sica A, Allavena P, Garlanda C and Locati M (2009) Tumor-associated macrophages and the related myeloid-derived suppressor cells as a paradigm of the diversity of macrophage activation. Hum Immunol 70, 325-330.
105. Marisa L, de Reynies A, Duval A, Selves J, Gaub MP, Vescovo L, Etienne-Grimaldi MC, Schiappa R, Guenot D, Ayadi M et al. (2013) Gene expression classification of colon cancer into molecular subtypes: characterization, validation, and prognostic value. PLoS Med 10, e1001453.
106. Massague J and Obenauf AC (2016) Metastatic colonization by circulating tumour cells. Nature 529, 298-306.
107. Masuda M, Uno Y, Ohbayashi N, Ohata H, Mimata A, Kukimoto-Niino M, Moriyama H, Kashimoto S, Inoue T, Goto N et al. (2016) TNIK inhibition abrogates colorectal cancer stemness. Nat Commun 7, 12586.
108. Matano M, Date S, Shimokawa M, Takano A, Fujii M, Ohta Y, Watanabe T, Kanai T and Sato T (2015) Modeling colorectal cancer using CRISPR-Cas9-mediated engineering of human intestinal organoids. Nat Med 21, 256-262.
109. Mathonnet M (2014) Hallmarks in colorectal cancer: angiogenesis and cancer stem-like cells. World J Gastroenterol 20, 4189.
110. Matsushita H, Vesely MD, Koboldt DC, Rickert CG, Uppaluri R, Magrini VJ, Arthur CD, White JM, Chen Y-S, Shea LK et al. (2012) Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting. Nature 482, 400-404.
111. Maywald RL, Doerner SK, Pastorelli L, De Salvo C, Benton SM, Dawson EP, Lanza DG, Berger NA, Markowitz SD, Lenz H-J et al. (2015) IL-33 activates tumor stroma to promote intestinal polyposis. Proc Natl Acad Sci USA 112, E2487-E2496.
112. Merika E, Saif MW, Katz A, Syrigos K, Syrigos C and Morse M (2010) Review. Colon cancer vaccines: an update. In Vivo 24, 607-628.
113. Merlos-Suarez A, Barriga FM, Jung P, Iglesias M, Cespedes MV, Rossell D, Sevillano M, Hernando-Momblona X, da Silva-Diz V, Munoz P et al. (2011) The intestinal stem cell signature identifies colorectal cancer stem cells and predicts disease relapse. Cell Stem Cell 8, 511-524.
114. Metcalfe C, Kljavin NM, Ybarra R and de Sauvage FJ (2014) Lgr5+ stem cells are indispensable for radiationinduced intestinal regeneration. Cell Stem Cell 14, 149-159.
115. Mlecnik B, Bindea G, Angell HK, Maby P, Angelova M, Tougeron D, Church SE, Lafontaine L, Fischer M, Fredriksen T et al. (2016a) Integrative analyses of colorectal cancer show immunoscore is a stronger predictor of patient survival than microsatellite instability. Immunity 44, 698-711.
116. Mlecnik B, Bindea G, Kirilovsky A, Angell HK, Obenauf AC, Tosolini M, Church SE, Maby P, Vasaturo A, Angelova M et al. (2016b) The tumor microenvironment and Immunoscore are critical determinants of dissemination to distant metastasis. Sci Transl Med 8, 327ra26.
117. Moehler M, Delic M, Goepfert K, Aust D, Grabsch HI, Halama N, Heinrich B, Julie C, Lordick F, Lutz MP et al. (2016) Immunotherapy in gastrointestinal cancer: recent results, current studies and future perspectives. Eur J Cancer 59, 160-170.
118. Naito Y, Saito K, Shiiba K, Ohuchi A, Saigenji K, Nagura H and Ohtani H (1998) CD8+ T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer. Cancer Res 58, 3491-3494.
119. Neuzillet C, Tijeras-Raballand A, Cohen R, Cros J, Faivre S, Raymond E and de Gramont A (2015) Targeting the TGFbeta pathway for cancer therapy. Pharmacol Ther 147, 22-31.
120. Nowell PC (1976) The clonal evolution of tumor cell populations. Science 194, 23-28.
121. Obenauf AC and Massague J (2015) Surviving at a distance: organ-specific metastasis. Trends Cancer 1, 76-91.
122. O’Brien CA, Pollett A, Gallinger S and Dick JE (2007) A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 445, 106-110.
123. Oskarsson T, Acharyya S, Zhang XH-F, Vanharanta S, Tavazoie SF, Morris PG, Downey RJ, Manova-Todorova K, Brogi E and Massague J (2011) Breast cancer cells produce tenascin C as a metastatic niche component to colonize the lungs. Nat Med 17, 867-874.
124. Oskarsson T, Batlle E and Massague J (2014) Metastatic stem cells: sources, niches, and vital pathways. Cell Stem Cell 14, 306-321.
125. Padua D, Zhang XH, Wang Q, Nadal C, Gerald WL, Gomis RR and Massague J (2008) TGFbeta primes breast tumors for lung metastasis seeding through angiopoietin-like 4. Cell 133, 66-77.
126. Palucka AK and Coussens LM (2016) The basis of oncoimmunology. Cell 164, 1233-1247.
127. Pickup M, Novitskiy S and Moses HL (2013) The roles of TGFbeta in the tumour microenvironment. Nat Rev Cancer 13, 788-799.
128. Pierce GB and Speers WC (1988) Tumors as caricatures of the process of tissue renewal: prospects for therapy by directing differentiation. Cancer Res 48, 1996-2004.
129. Prahallad A, Sun C, Huang S, Di Nicolantonio F, Salazar R, Zecchin D, Beijersbergen RL, Bardelli A and Bernards R (2012) Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature 483, 100-103.
130. Putoczki TL, Thiem S, Loving A, Busuttil RA, Wilson NJ, Ziegler PK, Nguyen PM, Preaudet A, Farid R, Edwards KM et al. (2013) Interleukin-11 is the dominant IL-6 family cytokine during gastrointestinal tumorigenesis and can be targeted therapeutically. Cancer Cell 24, 257-271.
131. Puzzoni M, Silvestris N, Leone F, Giampieri R, Faloppi L, Demurtas L, Dell’Aquila E, Marino D, Brunetti O, Garattini SK et al. (2016) The immune revolution in gastrointestinal tumours: leading the way or just following? Target Oncol 11, 593-603.
132. Quail DF and Joyce JA (2013) Microenvironmental regulation of tumor progression and metastasis. Nat Med 19, 1423-1437.
133. Ricci-Vitiani L, Lombardi DG, Pilozzi E, Biffoni M, Todaro M, Peschle C and De Maria R (2007) Identification and expansion of human colon-cancer-initiating cells. Nature 445, 111-115.
134. Rieder F, Kessler SP, West GA, Bhilocha S, De La Motte C, Sadler TM, Gopalan B, Stylianou E and Fiocchi C (2011) Inflammation-induced endothelial-to-mesenchymal transition: a novel mechanism of intestinal fibrosis. Am J Pathol 179, 2660-2673.
135. Roepman P, Schlicker A, Tabernero J, Majewski I, Tian S, Moreno V, Snel MH, Chresta CM, Rosenberg R, Nitsche U et al. (2014) Colorectal cancer intrinsic subtypes predict chemotherapy benefit, deficient mismatch repair and epithelial-to-mesenchymal transition. Int J Cancer 134, 552-562.
136. Rooney MS, Shukla SA, Wu CJ, Getz G and Hacohen N (2015) Molecular and genetic properties of tumors associated with local immune cytolytic activity. Cell 160, 48-61.
137. Ropponen KM, Eskelinen MJ, Lipponen PK, Alhava E and Kosma V-M (1997) Prognostic value of tumour-infiltrating lymphocytes (TILs) in colorectal cancer. J Pathol 182, 318-324.
138. Roulois D, Loo Yau H, Singhania R, Wang Y, Danesh A, Shen SY, Han H, Liang G, Jones PA, Pugh TJ et al. (2015) DNA-demethylating agents target colorectal cancer cells by inducing viral mimicry by endogenous transcripts. Cell 162, 961-973.
139. Sadanandam A, Lyssiotis CA, Homicsko K, Collisson EA, Gibb WJ, Wullschleger S, Ostos LCG, Lannon WA, Grotzinger C, Del Rio M et al. (2013) A colorectal cancer classification system that associates cellular phenotype and responses to therapy. Nat Med 19, 619-625.
140. Schepers AG, Snippert HJ, Stange DE, van den Born M, van Es JH, van de Wetering M and Clevers H (2012) Lineage tracing reveals Lgr5+ stem cell activity in mouse intestinal adenomas. Science 337, 730-735.
141. Schlicker A, Beran G, Chresta CM, McWalter G, Pritchard A, Weston S, Runswick S, Davenport S, Heathcote K, Castro DA et al. (2012) Subtypes of primary colorectal tumors correlate with response to targeted treatment in colorectal cell lines. BMC Med Genomics 5, 66.
142. Schreiber RD, Old LJ and Smyth MJ (2011) Cancer immunoediting: integrating immunity’s roles in cancer suppression and promotion. Science 331, 1565-1570.
143. Schwitalla S, Fingerle AA, Cammareri P, Nebelsiek T, Goktuna SI, Ziegler PK, Canli O, Heijmans J, Huels DJ, Moreaux G et al. (2013) Intestinal tumorigenesis initiated by dedifferentiation and acquisition of stem-cell-like properties. Cell 152, 25-38.
144. Seshagiri S, Stawiski EW, Durinck S, Modrusan Z, Storm EE, Conboy CB, Chaudhuri S, Guan Y, Janakiraman V, Jaiswal BS et al. (2012) Recurrent R-spondin fusions in colon cancer. Nature 488, 660-664.
145. Sharma P and Allison JP (2015) The future of immune checkpoint therapy. Science 348, 56-61.
146. Shinagawa K, Kitadai Y, Tanaka M, Sumida T, Kodama M, Higashi Y, Tanaka S, Yasui W and Chayama K (2010) Mesenchymal stem cells enhance growth and metastasis of colon cancer. Int J Cancer 127, 2323-2333.
147. Shinagawa K, Kitadai Y, Tanaka M, Sumida T, Onoyama M, Ohnishi M, Ohara E, Higashi Y, Tanaka S, Yasui W et al. (2013) Stroma-directed imatinib therapy impairs the tumor-promoting effect of bone marrow-derived mesenchymal stem cells in an orthotopic transplantation model of colon cancer. Int J Cancer 132, 813-823.
148. Smith AL, Robin TP and Ford HL (2012) Molecular pathways: targeting the TGF-beta pathway for cancer therapy. Clin Cancer Res 18, 4514-4521.
149. Solito S, Falisi E, Diaz-Montero CM, Doni A, Pinton L, Rosato A, Francescato S, Basso G, Zanovello P, Onicescu G et al. (2011) A human promyelocytic-like population is responsible for the immune suppression mediated by myeloid-derived suppressor cells. Blood 118, 2254-2265.
150. Sonoshita M, Aoki M, Fuwa H, Aoki K, Hosogi H, Sakai Y, Hashida H, Takabayashi A, Sasaki M, Robine S et al. (2011) Suppression of colon cancer metastasis by Aes through inhibition of notch signaling. Cancer Cell 19, 125-137.
151. Sonoshita M, Itatani Y, Kakizaki F, Sakimura K, Terashima T, Katsuyama Y, Sakai Y and Taketo MM (2015) Promotion of colorectal cancer invasion and metastasis through activation of NOTCH-DAB1-ABL-RHOGEF protein TRIO. Cancer Discov 5, 198-211.
152. Sosa MS, Bragado P and Aguirre-Ghiso JA (2014) Mechanisms of disseminated cancer cell dormancy: an awakening field. Nat Rev Cancer 14, 611-622.
153. Sottoriva A, Kang H, Ma Z, Graham TA, Salomon MP, Zhao J, Marjoram P, Siegmund K, Press MF, Shibata D et al. (2015) A Big Bang model of human colorectal tumor growth. Nat Genet 47, 209-216.
154. Strauss DC and Thomas JM (2010) Transmission of donor melanoma by organ transplantation. Lancet Oncol 11, 790-796.
155. Strilic B, Yang L, Albarran-juarez J, Wachsmuth L, Han K, Müller UC, Pasparakis M and Offermanns S (2016) Tumour-cell-induced endothelial cell necroptosis via death receptor 6 promotes metastasis. Nature 536, 215-218.
156. Sun H-L, Zhou X, Xue Y-F, Wang K, Shen Y-F, Mao J-J, Guo H-F and Miao Z-N (2012) Increased frequency and clinical significance of myeloid-derived suppressor cells in human colorectal carcinoma. World J Gastroenterol 18, 3303-3309.
157. Swanton C (2012) Intratumor heterogeneity: evolution through space and time. Cancer Res 72, 4875-4882.
158. Takahashi N, Yamada Y, Furuta K, Honma Y, Iwasa S, Takashima A, Kato K, Hamaguchi T and Shimada Y (2014) Serum levels of hepatocyte growth factor and epiregulin are associated with the prognosis on anti-EGFR antibody treatment in KRAS wild-type metastatic colorectal cancer. Br J Cancer 110, 2716-2727.
159. Taketo MM (2009) Role of bone marrow-derived cells in colon cancer: lessons from mouse model studies. J Gastroenterol 44, 93-102.
160. Tauriello DVF and Batlle E (2016) Trends in cancer targeting the microenvironment in advanced colorectal cancer. Trends Cancer 2, 495-504.
161. Tenbaum SP, Ordóñez-Morán P, Puig I, Chicote I, Arquès O, Landolfi S, Fernández Y, Herance JR, Gispert JD, Mendizabal L et al. (2012) β-catenin confers resistance to PI3K and AKT inhibitors and subverts FOXO3a to promote metastasis in colon cancer. Nat Med 18, 892-901.
162. Tetteh PW, Basak O, Farin HF, Wiebrands K, Kretzschmar K, Begthel H, Van Den Born M, Korving J, De Sauvage F, Van Es JH et al. (2016) Replacement of lost Lgr5-positive stem cells through plasticity of their enterocyte-lineage daughters. Cell Stem Cell 18, 203-213.
163. Tetteh PW, Farin HF and Clevers H (2015) Plasticity within stem cell hierarchies in mammalian epithelia. Trends Cell Biol 25, 100-108.
164. Thomas DA and Massague J (2005) TGF-beta directly targets cytotoxic T cell functions during tumor evasion of immune surveillance. Cancer Cell 8, 369-380.
165. Tie J, Wang Y, Tomasetti C, Li L, Springer S, Kinde I, Silliman N, Tacey M, Wong H-L, Christie M et al. (2016) Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer. Sci Transl Med 8, E359-E386.
166. Todaro M, Gaggianesi M, Catalano V, Benfante A, Iovino F, Biffoni M, Apuzzo T, Sperduti I, Volpe S, Cocorullo G et al. (2014) CD44v6 is a marker of constitutive and reprogrammed cancer stem cells driving colon cancer metastasis. Cell Stem Cell 14, 342-356.
167. Tohme S, Yazdani HO, Al-Khafaji AB, Chidi AP, Loughran P, Mowen K, Wang Y, Simmons RL, Huang H and Tsung A (2016) Neutrophil extracellular traps promote the development and progression of liver metastases after surgical stress. Cancer Res 76, 1367-1380.
168. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J and Jemal A (2015) Global cancer statistics, 2012. CA Cancer J Clin 65, 87-108.
169. Ulivi P, Marisi G, Passardi A, Ulivi P, Marisi G and Passardi A (2016) Relationship between hypoxia and response to antiangiogenic therapy in metastatic colorectal cancer. Oncotarget 7, 46678-46691.
170. Urosevic J, Garcia-Albeniz X, Planet E, Real S, Cespedes MV, Guiu M, Fernandez E, Bellmunt A, Gawrzak S, Pavlovic M et al. (2014) Colon cancer cells colonize the lung from established liver metastases through p38 MAPK signalling and PTHLH. Nat Cell Biol 16, 685-694.
171. Valastyan S and Weinberg RA (2011) Tumor metastasis: molecular insights and evolving paradigms. Cell 147, 275-292.
172. Valent P, Bonnet D, De Maria R, Lapidot T, Copland M, Melo JV, Chomienne C, Ishikawa F, Schuringa JJ, Stassi G et al. (2012) Cancer stem cell definitions and terminology: the devil is in the details. Nat Rev Cancer 12, 767-775.
173. Valiente M, Obenauf AC, Jin X, Chen Q, Zhang XH-F, Lee DJ, Chaft JE, Kris MG, Huse JT, Brogi E et al. (2014) Serpins promote cancer cell survival and vascular cooption in brain metastasis. Cell 156, 1002-1016.
174. Van Cutsem E, Cervantes A, Adam R, Sobrero A, Van Krieken JH, Aderka D, Aranda Aguilar E, Bardelli A, Benson A, Bodoky G et al. (2016) ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol 27, 1386-1422.
175. Van Cutsem E, Tabernero J, Lakomy R, Prenen H, Prausova J, Macarulla T, Ruff P, van Hazel GA, Moiseyenko V, Ferry D et al. (2012) Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. J Clin Oncol 30, 3499-3506.
176. van Es JH, Sato T, van de Wetering M, Lyubimova A, Yee Nee AN, Gregorieff A, Sasaki N, Zeinstra L, van den Born M, Korving J et al. (2012) Dll1+ secretory progenitor cells revert to stem cells upon crypt damage. Nat Cell Biol 14, 1099-1104.
177. van Wyk HC, Park J, Roxburgh C, Horgan P, Foulis A and McMillan DC (2015) The role of tumour budding in predicting survival in patients with primary operable colorectal cancer: a systematic review. Cancer Treat Rev 41, 151-159.
178. Vermeulen L, De Sousa E Melo F, van der Heijden M, Cameron K, de Jong JH, Borovski T, Tuynman JB, Todaro M, Merz C, Rodermond H et al. (2010) Wnt activity defines colon cancer stem cells and is regulated by the microenvironment. Nat Cell Biol 12, 468-476.
179. Vermeulen L, Todaro M, de Sousa Mello F, Sprick MR, Kemper K, Perez Alea M, Richel DJ, Stassi G and Medema JP (2008) Single-cell cloning of colon cancer stem cells reveals a multi-lineage differentiation capacity. Proc Natl Acad Sci USA 105, 13427-13432.
180. Vinay DS, Ryan EP, Pawelec G, Talib WH, Stagg J, Elkord E, Lichtor T, Decker WK, Whelan RL, Kumara HMCS et al. (2015) Immune evasion in cancer: mechanistic basis and therapeutic strategies. Semin Cancer Biol 35, S185-S198.
181. Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA Jr and Kinzler KW (2013) Cancer genome landscapes. Science 339, 1546-1558.
182. Wielenga MCB, Colak S, Heijmans J, van Lidth de Jeude JF, Rodermond HM, Paton JC, Paton AW, Vermeulen L, Medema JP and van den Brink GR (2015) ERstress-induced differentiation sensitizes colon cancer stem cells to chemotherapy. Cell Rep 13, 490-494.
183. Woo JK, Kang JH, Kim B, Park BH, Shin KJ, Song SW, Kim JJ, Kim HM, Lee SJ and Oh SH (2015) Humanized anti-hepatocyte growth factor (HGF) antibody suppresses innate irinotecan (CPT-11) resistance induced by fibroblast-derived HGF. Oncotarget 6, 24047-24060.
184. Xiang B, Snook AE, Magee MS and Waldman SA (2013) Colorectal cancer immunotherapy. Discov Med 15, 301-308.
185. Yamamoto T, Kawada K, Itatani Y, Inamoto S, Okamura R, Iwamoto M, Miyamoto E, Chen-Yoshikawa TF, Hirai H, Hasegawa S et al. (2016) Loss of SMAD4 promotes lung metastasis of colorectal cancer by accumulation of CCR1+ tumor-associated neutrophils through CCL15-CCR1 axis. Clin Cancer Res, doi:10.1158/1078-0432.CCR-16-0520 [Epub ahead of print].
186. Yan KS, Chia LA, Li X, Ootani A, Su J, Lee JY, Su N, Luo Y, Heilshorn SC, Amieva MR et al. (2012) The intestinal stem cell markers Bmi1 and Lgr5 identify two functionally distinct populations. Proc Natl Acad Sci 109, 466-471.
187. Yang L, Pang Y and Moses HL (2010) TGF-beta and immune cells: an important regulatory axis in the tumor microenvironment and progression. Trends Immunol 31, 220-227.
188. Yonenaga Y, Mori A, Onodera H, Yasuda S, Oe H, Fujimoto A, Tachibana T and Imamura M (2005) Absence of smooth muscle actin-positive pericyte coverage of tumor vessels correlates with hematogenous metastasis and prognosis of colorectal cancer patients. Oncology 69, 159-166.
189. Zeisberg EM, Potenta S, Xie L, Zeisberg M and Kalluri R (2007) Discovery of endothelial to mesenchymal transition as a source for carcinoma-associated fibroblasts. Cancer Res 67, 10123-10128.
190. Zhang Y, Davis C, Shah S, Hughes D, Ryan JC, Altomare D and Pena MMO (2016) IL-33 promotes growth and liver metastasis of colorectal cancer in mice by remodeling the tumor microenvironment and inducing angiogenesis. Mol Carcinog 56, 272-287.
191. Zhang Q, Yang X, Pins M, Javonovic B, Kuzel T, Kim S-J, Parijs L Van, Greenberg NM, Liu V, Guo Y et al. (2005) Adoptive transfer of tumor-reactive transforming growth factor-beta-insensitive CD8+ T cells: eradication of autologous mouse prostate cancer. Cancer Res 65, 1761-1769.
192. Zitvogel L, Galluzzi L, Smyth MJ and Kroemer G (2013) Mechanism of action of conventional and targeted anticancer therapies: reinstating immunosurveillance. Immunity 39, 74-88.
193. Zlobec I, Lugli A, Zlobec I and Lugli A (2010) Epithelial mesenchymal transition and tumor budding in aggressive colorectal cancer: tumor budding as oncotarget. Oncotarget 1, 651-661.
194. Zumwalt TJ and Goel A (2015) Immunotherapy of metastatic colorectal cancer: prevailing challenges and new perspectives. Curr Colorectal Cancer Rep 11, 125-140.